Cerus Tops Q1 EPS by 2c
- ByInvesting.com-
Cerus (NASDAQ:CERS) reported Q1 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43 million versus the consensus estimate of...
Symbol | Exchange | Currency |
---|
Cerus (NASDAQ:CERS) reported Q1 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43 million versus the consensus estimate of...
The biotech industry has witnessed solid growth over the past year, in large measure attributable to the demand for drugs to fight COVID-19, among other diseases. The integration...
AAPL, ACIA, ACLS, AIRG, AIV, ALEX, AMH, ANET, AOSL, APPN, ARCB, ATGE, ATHN, ATR, ATRC, ATSG, BCOV, BFAM, BIO, BL, BLDR, BNFT, BRKR, BVX, CARB, CATM, CBPO, CBS, CC, CCRN, CECO,...
This week was all about the stimulus deal, so, since we still don’t have one, it makes complete sense that the market would move lower over these five days. It’s...
Stocks rose about 2% on Tuesday as three pieces of positive news helped the market to a third day of gains since last Thursday’s epic pullback. The biggest impact probably...
1. Bloom Energy CorporationBloom Energy Corporation (NYSE:BE) popped on Wednesday and exploded for 1.87, or 22%, to 10.27, after reaching a session high of 10.50, on 9.6 million...
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Neutral | Sell | Strong Sell | Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
308.08 | 308.49 | 301.30 | +7.89 | +2.63% | 2.30M | NYSE | |||
49.44 | 49.48 | 48.68 | +0.87 | +1.79% | 2.88M | NASDAQ | |||
8.37 | 8.47 | 8.16 | +0.24 | +2.95% | 6.64M | NYSE | |||
4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
32.74 | 32.75 | 31.69 | +0.89 | +2.81% | 4.93M | NYSE | |||
3.60 | 3.65 | 3.54 | +0.080 | +2.27% | 10.10M | NYSE | |||
1.085 | 1.10 | 1.01 | +0.0650 | +6.37% | 306.83K | NYSE | |||
1.205 | 1.23 | 1.19 | -0.0050 | -0.41% | 2.57M | NYSE | |||
46.26 | 46.28 | 45.16 | +1.36 | +3.03% | 1.89M | NYSE | |||
50.90 | 51.04 | 49.74 | -0.20 | -0.39% | 3.16M | NYSE | |||
43.51 | 43.66 | 43.24 | -0.11 | -0.25% | 5.55M | NYSE | |||
50.11 | 50.39 | 48.55 | +1.82 | +3.77% | 25.57M | NYSE | |||
0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
128.20 | 128.52 | 126.71 | +1.21 | +0.95% | 768.09K | NYSE | |||
183.19 | 183.33 | 171.07 | +13.45 | +7.93% | 967.46K | NYSE |